Annette Hastie to Adrenergic beta-Agonists
This is a "connection" page, showing publications Annette Hastie has written about Adrenergic beta-Agonists.
Connection Strength
0.437
-
Hastie AT, Wu M, Foster GC, Hawkins GA, Batra V, Rybinski KA, Cirelli R, Zangrilli JG, Peters SP. Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use. Respir Res. 2006 Feb 15; 7:25.
Score: 0.274
-
Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, Castro M, Chardon D, Erzurum SC, Israel E, Montealegre F, Wenzel SE, Peters SP, Meyers DA, Bleecker ER. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting ß agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med. 2014 Mar; 2(3):204-13.
Score: 0.119
-
Weathington N, O'Brien ME, Radder J, Whisenant TC, Bleecker ER, Busse WW, Erzurum SC, Gaston B, Hastie AT, Jarjour NN, Meyers DA, Milosevic J, Moore WC, Tedrow JR, Trudeau JB, Wong HP, Wu W, Kaminski N, Wenzel SE, Modena BD. BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications. Am J Respir Crit Care Med. 2019 10 01; 200(7):837-856.
Score: 0.044